Background and Aims: The combination of basal insulin (BI) and GLP-1 receptor agonists (GLP-1RAs) is a rational and effective therapy for patients with uncontrolled type 2 diabetes (T2D). We compared the effectiveness of fixed and flexible BI/GLP-1RA combinations using routinely accumulated clinical data.
| INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are prioritized as second-line therapy for the treatment of type 2 diabetes (T2D), especially in patients with a history of cardiovascular disease (CVD) or when there is a need to avoid weight gain and hypoglycaemia. 1 Randomized controlled trials (RCTs) have shown that addition of GLP-1RA is more effective in reducing HbA1c than addition of basal insulin (BI) in patients with uncontrolled T2D who are undergoing oral therapy. 2, 3 GLP-1RAs are associated with a low risk of hypoglycaemia and have extra-glycaemic effects, including reduction in body weight and blood pressure. 4, 5 Notably, GLP-1RAs as a class improve cardiovascular outcomes in T2D patients with established CVD. 6 These benefits justify the positioning of GLP-1RAs as the first injectable therapy in most T2D patients as an alternative to insulin. 1 For patients who are already using BI, addition of a GLP-1RA is a rational strategy when intensification is needed. BI and GLP-1RAs potentiate each other by acting through different mechanisms in different tissues. 7, 8 Addition of GLP-1RAs to a basal oral therapy is as effective as addition of bolus insulin with respect to glycaemic control, but with lower risk of hypoglycaemia and weight gain, and lower insulin doses. 9 Therapeutic inertia in treating patients with uncontrolled T2D can worsen cardiovascular outcomes, 10 and intensification of a basal oral regimen is often delayed in clinical practice 11 13 However, many patients in clinical practice do not receive high doses of BI, implying that the GLP-1RA dose in the FRC may be under-titrated. Compared with FRCs, flexible combinations of BI and GLP-1RA are burdened by the higher numbers of injections and regimen complexity, but have the advantage of being able to combine any BI with any GLP-1RA, each at the desired dose.
Meta-analyses of RCTs reported similar benefits of fixed and flexible BI/GLP-1RA combinations in patients with T2D who were already using BI and required intensification of glucose control, 14, 15 but no RCT directly compared the fixed and flexible combinations. In the absence of data from RCTs, observational studies, if well designed and carefully conducted, can provide medium-level evidence to inform clinical practice. 16 Real-world studies are hypothesis-generating and cannot substitute for RCTs, 17 but they can guide the design of dedicated RCTs. Retrospective real-world studies are particularly attractive, as they can rapidly gather data from large heterogeneous populations that are representative of those seen in routine clinical practice. 18 We herein report the results of a retrospective real-world multicentre study that was conducted to compare the effectiveness of the fixed and the flexible BI/GLP-1RA combination concerning glycaemic and extra-glycaemic endpoints.
| MATERIALS AND METHODS

| Study design
The GLP-1REWIN (GLP-1 REceptor agonists and real World evI-deNce) study was a retrospective real-world study conducted at six diabetes specialist outpatient clinics in the Veneto region, north-east Italy. The protocol has been registered at ClinicalTrials.gov (NCT03959865). The general objective of the study was to evaluate the effectiveness of GLP-1RAs concerning glycaemic and extraglycaemic endpoints in real-world clinical practice from 2010 to 2018.
The study was conducted at diabetes centres because only diabetologists could prescribe GLP-1RAs in Italy during the study period. Data were collected retrospectively by automatically interrogating the same electronic chart at all centres (MyStar Connect Smart Digital Clinic, Meteda, San Benedetto del Tronto, Italy). A dedicated software was developed to extract all relevant anonymized patient information for placement into a clinical research form without manual intervention.
Suitability of this data collection approach for performing real-world comparative effectiveness studies has been demonstrated extensively. [19] [20] [21] [22] The study was promoted by the University Hospital of Padova and approved by the respective ethical committees of each participating centre. As data were anonymized at time of automatic extraction, making patient re-identification impossible, no informed consent was required according to national regulations concerning retrospective studies.
| Cohort identification
Although the GLP-1REWIN study collected retrospective data concerning all GLP-1RAs since 2010, the present analysis focused only on the combination of BI and GLP-1RAs. In Italy, the cost of initiation of an FRC of BI/GLP-1RA was reimbursed only for patients who were already using BI. Thus, for this specific analysis, we included data concerning all patients aged 18-80 years with a diagnosis of T2D for at least 1 year, as recorded in the chart, who were already using BI and initiated a GLP-1RA that was available on the market between 1 January 2010 and 31 December 2018 in addition to a regimen that comprised BI with or without oral agents. Available GLP-1RAs were: exenatide twice daily or once weekly, liraglutide, lixisenatide, dulaglutide and FRCs of BI/GLP-1RA. Albiglutide and semaglutide were not available. No restriction to the type or dosage of concomitant oral agents was imposed. Patients using basal-bolus insulin and those who initiated a new GLP-1RA, switching from another GLP-1RA-based regimen, were excluded. No other exclusion criteria were applied.
| Data extraction
The baseline visit date was set as the date a patient attended the outpatient clinic and received for the first time a new prescription of a GLP-1RA. The following clinical characteristics and laboratory data were collected from the electronic chart up to 90 days before baseline: age, sex, diabetes duration, body height and weight, body mass index (BMI), waist circumference, systolic and diastolic blood pressure (SBP and DBP), fasting plasma glucose (FPG), HbA1c, total cholesterol, HDL cholesterol, triglycerides (LDL cholesterol calculated using 
| Objectives and endpoints
In this analysis, we compared changes in glycaemic (HbA1c and fasting plasma glucose) and extra-glycaemic (body weight and systolic blood pressure) effectiveness parameters between patients who initi- datasets, we performed a sub-analysis wherein the flexible group was restricted to patients who added liraglutide to basal oral therapy.
| Analysis of treatment cost
In exploratory analyses performed in the ITT dataset for the primary endpoint, using PSM or MVA, we compared the estimated economic cost per patient for adding a GLP-1RA to BI as a fixed or a flexible combination. The treatment cost was estimated according to the market price currently specified in Italy for each BI, GLP-1RA and the FRCs, as well as for needles (Table S1 ). The types of drugs and dose prescribed at baseline were used to determine the weekly cost of treatment. For patients who continued treatment and underwent titration, the average dose between baseline and follow-up was used.
To determine the final estimated total cost of BI and GLP-1RA therapy for each patient, the average weekly cost was multiplied by the interval from baseline to follow-up in weeks.
| Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD) if normally distributed or as median (interquartile range) if nonnormally distributed. Non-normal variables were log-transformed before being analysed by parametric tests. Categorical variables were expressed as percentage. All analyses were performed separately in the ITT and PP datasets. The comparison of baseline characteristics between two groups (fixed vs flexible) was performed using the unpaired 2-tailed Student's t test for continuous variables and the chi square test for categorical variables. To evaluate the balance between the two groups, in addition to P values, we calculated the standardized mean difference (SMD). Good balance is conventionally set at SMD <0.10, meaning that, for continuous variables, the between-group difference must be <10% the pooled standard deviation. The intra-group change in effectiveness endpoint variables from baseline to end of follow-up was analysed using the paired 2-tailed Student's t test. We then calculated the change in endpoint variables within each group, which were compared using the unpaired 2-tailed Student's t test. To address channelling bias, that is, differences in baseline characteristics between the two groups that drive differential outcomes, we used two approaches. In the primary analysis, we performed a propensity score matching (PSM), in which patients in the fixed group were mat- adjusted for all clinical characteristics that differed at baseline between the two groups with a P value <0.10 (Model 1) or for all clinical variables used to compute PS (Model 2). For both PSM and MVA, full datasets were needed for all variables used to compute PS or to be entered into the regression models. Therefore, missing data were handled with multiple imputation (MI), which was performed using a fully conditional specification (FCS) algorithm, 23 obtaining 10 imputed datasets. All covariates with less than 50% of missing values were included as predictors in the imputation process. Outcome variables were not imputed and imputed data were used only for MVA and for computing PS. Outcome analysis after PSM and MVA was performed on each imputed dataset and pooled estimated treatment differences (ETDs) are presented. 24 For PSM, matched cohorts from each of the 10 imputed datasets varied slightly in composition and size because the 10 imputed datasets were different and independent. Only for representation purpose, the PSM groups from the first imputed dataset are shown. Statistical analyses were performed using SAS version 9.4 (TS1M4) or higher and a 2-tailed P value <.05 was considered statistically significant. Baseline characteristics of patients are summarized in Table 1 . .82
| RESULTS
| Patient disposition and characteristics
Note. The two groups are compared before and after propensity score matching (PSM). In addition to P values, standardized mean differences (SMD) are shown. Only observed data are shown. For matched cohorts, the first imputed dataset (out of 10) is reported. Abbreviations: ACEi, angiotensin converting enzyme inhibitors; ALT, alanine aminotransferase; APT, anti-platelet therapies; ARBs, angiotensin receptor blockers; AST, aspartic aminotransferase; BMI, body mass index; CCB, calcium channel blockers; CKD, chronic kidney disease; DBP, diastolic blood pressure; DME, diabetic macular edema; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL, high density lipoprotein. IHD, ischemic heart disease; LVH, left ventricular hypertrophy; OAT, oral anticoagulant therapy; SBP, systolic blood pressure; TIA, transient ischaemic attack. a SMDs are shown as the mean of SMD in the 10 imputed datasets.
b
The combination of GLP-1RAs and SGLT-2 inhibitors was not reimbursed.
| Observed changes in dosages and effectiveness endpoints
We first performed an unadjusted analysis of the unmatched ITT 
| Primary ITT comparative effectiveness analysis
The 131 patients in the fixed group were matched 1:1 with 131 patients in the flexible group using PSM. As shown in Table 1 (and represented graphically in Figure S1A ), the matched groups were very well balanced with respect to all the clinical characteristics considered at baseline, thereby allowing a direct comparison for the pri- Exclusion of patients from the matched cohorts for whom body weight values were missing resulted in a slight imbalance in baseline use of sulphonylureas and prevalence of maculopathy ( Figure S1B ).
When this residual imbalance was adjusted for, the ETD for body weight was 1.14 kg in favour of the flexible combination (P = .049). As in the overall population, the BI dose in the matched cohorts increased more in the fixed group than in the flexible group (ETD ± SE: 5.1 ± 0.9 units; P < .001) (Table S2 ). After accounting for the difference in BI dose, the ETD for body weight in favour of the flexible group was reduced to 0.9 kg and was no longer significant (P = .148).
No significant difference was noted for change in FPG and SBP between the two matched cohorts ( Table 2 ). The residual imbalances in baseline covariates secondary to the exclusion of participants for whom SBP or FPG values at baseline or follow-up were missing ( Figure S1C and S1D) did not alter the outcome comparison.
The estimated total cost of treatment was, on average, 878.8 
| Multivariable regression analysis
As an alternative approach to PSM, we addressed channelling bias by MVA, including all patients in both groups for whom endpoint data were available (Table 3 ). In the more parsimonious Model 1, HbA1c declined by 0.33% ± 0.16% more in the fixed group (P = .038), 
| PP analyses
In the PP dataset, we retained only patients who continued the BI/GLP-1RA combination at follow-up. PSM yielded 109 patients in each group for analysis of the primary endpoint (Table S3 ). Balance was good after PSM, with the exception of the baseline prevalence of microangiopathy ( Figure S1E ). Change from baseline in HbA1c was identical between the two groups (ETD, 0.02%; P = .934) ( Table 2) , even after adjustment for baseline microangiopathy. As observed for the primary analysis, exclusion of some patients for whom data for secondary endpoints were missing amplified the between-group imbalance, leading to the need for further adjustment (Figure S1F-H) .
Change from baseline in body weight was still in favour of the flexible combination (ETD, 1.64 ± 0.62; P = .009), even after adjustment for residual imbalance in gender, SBP, microangiopathy, use of glitazones and anticoagulant therapy (P = .007). No significant difference was observed for change in FPG and SBP. According to MVA performed on the PP dataset, HbA1c declined to the same extent in the two groups, whereas body weight declined by 1.9 kg more in the flexible group (P ≤ .001) in both models. No significant difference was observed for change in FPG and SBP (Table 3) . 
T A B L E 2 Outcome analysis
| Sub-analysis
We compared the IdegLira FRC with the flexible combination of BI with liraglutide. In the ITT dataset, PSM yielded two groups comprising 127 patients each, which were well balanced for baseline covariates (Figure S1I and S1J). As shown in Table S4 , there was no significant between-group difference in HbA1c decline, but body weight declined by 1.25 kg more in the flexible group, even after adjustment for residual confounders (P = .034). No significant difference was noted for change in FPG and SBP. These results were confirmed in the PP dataset. MVA performed on the ITT or PP datasets and in both models still showed no significant difference in change in HbA1c between groups, but a significantly higher decline in body weight in the flexible group (Table S5 ).
| DISCUSSION
In this real-world retrospective multicentre study, we show that initia- Furthermore, the FRC always included insulin degludec (vs 6.7% in the flexible group), which has been shown to improve FPG more than insulin glargine-100 and -300 in treat-to-target RCTs. 25, 26 As a collateral note, IglarLixi was not represented in the fixed group probably because, in Italy, it entered the market after IdegLira and the overall use of lixisenatide was limited (as evidenced by the small proportion of patients using lixisenatide in the flexible group). A better adherence to the single daily injection also could have contributed to the glycaemic effect of the FRC, but this is speculative as information concerning drug dispensing and refill rates was not available. As the study was a retrospective collection of data recorded for clinical purposes, there was no pre-specified glucose target. In fact, titration of the BI dose was suboptimal in both groups, because FPG remained far from internationally recognized targets despite relatively lower insulin requirements (~0.2 units/kg). Nonetheless, an increase in BI dose from 20 to 26 units at 6 months in the fixed group was beyond that observed in the ORBIT study for patients using basal oral therapy. 27 Further improvements in HbA1c could be expected in both groups if insulin doses were appropriately titrated. Of note, we found that similar or greater glycaemic benefit was achieved with the fixed combination at a lower cost than with the flexible combination. It could be speculated that equal insulin titration in the two groups would limit weight decrease in the flexible group, because the GLP-1RA dose RCTs. 17 We addressed such bias using PSM and MVA. Although PSM generated two cohorts well-balanced for all measured variables and assumes no linear relationships between covariates and the outcome, it reduces sample size and statistical power. MVA retains all patients in the analysis, but assumes multiple linear relations that may not hold true. Notably, quite similar results were obtained with these two different approaches, suggesting an appropriate handling of known confounders. However, residual confounding by unmeasured variables cannot be eliminated without randomization. Importantly, the reasons underlying the choice of a fixed or flexible combination may have driven the differential outcome. 
